Microbot Medical (MBOT) Net Income towards Common Stockholders (2010 - 2026)

Microbot Medical has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 25.85% year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at -$14.2 million (down 18.54% YoY), and the FY2025 full-year result was -$13.5 million, down 17.61% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.7 million, down from -$3.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$2.0 million in Q4 2023, with the low at -$3.7 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$3.0 million across 5 years, with a median of -$3.2 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 34.9% — and 2024, when it plunged 66.19%.
• Microbot Medical's Net Income towards Common Stockholders stood at -$3.0 million in 2022, then surged by 31.81% to -$2.0 million in 2023, then tumbled by 66.19% to -$3.4 million in 2024, then declined by 2.12% to -$3.5 million in 2025, then fell by 5.98% to -$3.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.7 million (Q1 2026), -$3.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.